579 related articles for article (PubMed ID: 11127921)
1. CD34 immunohistochemistry in female genital tract carcinosarcoma (malignant mixed müllerian tumors) supports a dominant role of the carcinomatous component.
Costa MJ; Guinee D
Appl Immunohistochem Mol Morphol; 2000 Dec; 8(4):293-9. PubMed ID: 11127921
[TBL] [Abstract][Full Text] [Related]
2. Epidermal growth factor receptor and c-erbB-2 oncoprotein expression in female genital tract carcinosarcomas (malignant mixed müllerian tumors). Clinicopathologic study of 82 cases.
Costa MJ; Walls J
Cancer; 1996 Feb; 77(3):533-42. PubMed ID: 8630962
[TBL] [Abstract][Full Text] [Related]
3. Carcinoma (malignant mixed müllerian [mesodermal] tumor) of the uterus and ovary. Correlation of clinical, pathologic, and immunohistochemical features in 29 cases.
Costa MJ; Khan R; Judd R
Arch Pathol Lab Med; 1991 Jun; 115(6):583-90. PubMed ID: 1710102
[TBL] [Abstract][Full Text] [Related]
4. Ovarian carcinosarcoma associated with bilateral tubal intraepithelial carcinoma: a case report.
Brustmann H
Int J Gynecol Pathol; 2013 Jul; 32(4):384-9. PubMed ID: 23722511
[TBL] [Abstract][Full Text] [Related]
5. Expression of CD10 in malignant müllerian mixed tumors and adenosarcomas: an immunohistochemical study.
Mikami Y; Hata S; Kiyokawa T; Manabe T
Mod Pathol; 2002 Sep; 15(9):923-30. PubMed ID: 12218209
[TBL] [Abstract][Full Text] [Related]
6. p53 gene mutation in female genital tract carcinosarcomas (malignant mixed müllerian tumors): a clinicopathologic study of 74 cases.
Costa MJ; Vogelsan J; Young LJ
Mod Pathol; 1994 Aug; 7(6):619-27. PubMed ID: 7991520
[TBL] [Abstract][Full Text] [Related]
7. Uterine Carcinosarcomas: Clinical, Histopathologic and Immunohistochemical Characteristics.
Chen X; Arend R; Hamele-Bena D; Tergas AI; Hawver M; Tong GX; Wright TC; Wright JD
Int J Gynecol Pathol; 2017 Sep; 36(5):412-419. PubMed ID: 28700424
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors in uterine carcinosarcoma: a clinicopathologic study of 25 patients.
Iwasa Y; Haga H; Konishi I; Kobashi Y; Higuchi K; Katsuyama E; Minamiguchi S; Yamabe H
Cancer; 1998 Feb; 82(3):512-9. PubMed ID: 9452269
[TBL] [Abstract][Full Text] [Related]
9. SATB2 Expression Is Sensitive but Not Specific for Osteosarcomatous Components of Gynecologic Tract Carcinosarcomas: A Clinicopathologic Study of 60 Cases.
Sangoi AR; Kshirsagar M; Horvai AE; Roma AA
Int J Gynecol Pathol; 2017 Mar; 36(2):140-145. PubMed ID: 27294605
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the relationship between adenosarcoma and carcinosarcoma and a hypothesis of the histogenesis of uterine sarcomas.
Seidman JD; Chauhan S
Int J Gynecol Pathol; 2003 Jan; 22(1):75-82. PubMed ID: 12496702
[TBL] [Abstract][Full Text] [Related]
11. PD-L1 Expression in Carcinosarcomas of the Gynecologic Tract: A Potentially Actionable Biomarker.
Pinto A; Mackrides N; Nadji M
Appl Immunohistochem Mol Morphol; 2018 Jul; 26(6):393-397. PubMed ID: 27801734
[TBL] [Abstract][Full Text] [Related]
12. Endometrioid carcinomas of the uterine corpus with sex cord-like formations, hyalinization, and other unusual morphologic features: a report of 31 cases of a neoplasm that may be confused with carcinosarcoma and other uterine neoplasms.
Murray SK; Clement PB; Young RH
Am J Surg Pathol; 2005 Feb; 29(2):157-66. PubMed ID: 15644772
[TBL] [Abstract][Full Text] [Related]
13. WT1 immunoprofiling and comparison of malignant Mullerian mixed tumors of the female genital tract.
Franko A; Magliocco AM; Duan Q; Duggan MA
Int J Gynecol Pathol; 2010 Sep; 29(5):452-8. PubMed ID: 20736771
[TBL] [Abstract][Full Text] [Related]
14. The immunohistochemical profile of malignant mixed müllerian tumor. Overlap with endometrial adenocarcinoma.
Meis JM; Lawrence WD
Am J Clin Pathol; 1990 Jul; 94(1):1-7. PubMed ID: 1694389
[TBL] [Abstract][Full Text] [Related]
15. HER2 testing of gynecologic carcinosarcomas: tumor stratification for potential targeted therapy.
Rottmann D; Snir OL; Wu X; Wong S; Hui P; Santin AD; Buza N
Mod Pathol; 2020 Jan; 33(1):118-127. PubMed ID: 31477811
[TBL] [Abstract][Full Text] [Related]
16. Folate Receptor Alpha Is Preferentially Expressed in the Carcinoma Component of Endometrial Carcinosarcomas: A Potential Target for Adjuvant Therapy.
Hanley KZ; Horowitz IR; Gordon A; Meisel J; Khanna N
Int J Gynecol Pathol; 2021 Sep; 40(5):501-509. PubMed ID: 33323854
[TBL] [Abstract][Full Text] [Related]
17. Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus: clinicoimmunohistochemical and histogenetic characteristics.
Kedzia W; Pruski D; Iwaniec K; Przybylski M; Friebe Z; Rajpert-Kedzia H
Folia Histochem Cytobiol; 2012; 50(4):513-8. PubMed ID: 23264213
[TBL] [Abstract][Full Text] [Related]
18. Comparative analysis of P16 and P53 expression in uterine malignant mixed mullerian tumors.
Buza N; Tavassoli FA
Int J Gynecol Pathol; 2009 Nov; 28(6):514-21. PubMed ID: 19851197
[TBL] [Abstract][Full Text] [Related]
19. Pax8: a marker for carcinoma of Müllerian origin in serous effusions.
Tong GX; Devaraj K; Hamele-Bena D; Yu WM; Turk A; Chen X; Wright JD; Greenebaum E
Diagn Cytopathol; 2011 Aug; 39(8):567-74. PubMed ID: 20607683
[TBL] [Abstract][Full Text] [Related]
20. Mutational and Immunophenotypic Profiling of a Series of 8 Tubo-ovarian Carcinosarcomas Revealed a Monoclonal Origin of the Disease.
Trento M; Munari G; Carraro V; Lanza C; Salmaso R; Pizzi S; Santoro L; Chiarelli S; Dal Santo L; Nardelli GB; Saccardi C; Nicoletto O; Baldoni A; Rugge M; Fassan M
Int J Gynecol Pathol; 2020 Jul; 39(4):305-312. PubMed ID: 31688243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]